Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.

Expert opinion on drug metabolism & toxicology - 1 Oct 2020

Petrykey Kateryna, Andelfinger Gregor U, Laverdière Caroline, Sinnett Daniel, Krajinovic Maja

Abstract excerpt

INTRODUCTION: Cardiovascular diseases are the main cause of treatment-related morbidity and mortality in childhood cancer patients. Anthracyclines, one of the most common chemotherapeutic agents in treatment regimens, are implicated in chemotherapy-induced cardiotoxicity. AREAS COVERED: This review describes the pharmacogenomic markers related to anthracycline-induced cardiotoxicity affecting childhood cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiotoxicity

Share to Chemotherapy-induced cardiotoxicity and mitigation

Share to Genetic Predisposition to Disease

Share to Neoplasms

Share to Pharmacogenetics

Source

Identifiers

PMID: 32772754
DOI: 10.1080/17425255.2020.1807937

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.PMID 32772754Read ↗

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.Semantic proximity Read ↗

Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.Semantic proximity Read ↗

The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.Semantic proximity Read ↗

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Current views on anthracycline cardiotoxicity.Semantic proximity Read ↗

Inter-Individual Variation and Cardioprotection in Anthracycline-Induced Heart FailureSemantic proximity Read ↗

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell ModelingSemantic proximity Read ↗

Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.Semantic proximity Read ↗

Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer.Semantic proximity Read ↗

Prognostic Factors for Cardiotoxicity Among Children With Cancer: Definition, Causes and Diagnosis With Omics TechnologiesSemantic proximity Read ↗

Clinical prediction models for anthracycline-associated cardiotoxicity among pediatric cancer survivors--ready for prime time?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.